Quantcast

Onxeo encouraged by intermediate results from the first part of the DRIIV-1b study evaluating AsiDNA in combination with chemotherapy

Onxeo said it stabilized disease without tumor progression for two of the three treated patients who are still receiving treatment with AsiDNA™ plus carboplatin, with reaching satisfactory tolerance allowing the continuation of the study to evaluate AsiDNA™ in combination with carboplatin and paclitaxel, a reference treatment protocol for many cancers.

Read more